Alnylam Pharmaceuticals, Inc.

FCM seeks investments across asset classes and around the world through a process of bottom-up fundamental research and analysis emphasizing capital preservation. Their investment strategies include Credit Investments, Long/Short Equity, Merger Arbitrage, Risk Arbitrage, Real Estate Investments and Direct Investments. Investment ideas compete for capital based on in-depth, critical assessment of specific risks and rewards. Risk is monitored and managed through rigorous and thorough analysis of each investment and, at the portfolio level, through risk management analytics and overlay and tail-risk hedging.

RTW Investments aims to generate attractive risk-adjusted returns through investments in securities, both equity and debt, long and short, of companies with a focus on the healthcare sector. The Funds will primarily invest in the equity and debt of public and private issuers globally, with a focus on the US and Europe. Derivatives are employed to improve payoff structures, as well as to construct hedges. The firm’s research process will be focused on a scientific approach to assessing and accurately defining the fundamental value of outcomes surrounding transformational events in the lifecycle of healthcare companies.

Bellevue AM is an active, fundamental research-based manager which utilizes a bottom-up investment and anti-cyclical approach, aiming to generate above-average returns while keeping risk under control and well monitored. They screen and invest in promising family and owner-managed companies based in Switzerland or the broader European continent through our family of Entrepreneur funds. The firm has become very adept at identifying high growth potential in new and emerging markets, particularly on the African continent. In addition to global equity and fixed income funds, Bellevue AM successfully manage multi-asset funds. A diverse family of ETF strategies (asset allocation with ETFs) rounds out the holistic profile. The firm’s in-house capital market research specialists systematically identify the most attractive asset classes, markets and sectors, as viewed from a holistic perspective. Their flagship investment vehicle, BB Biotech AG invests in fast-growing biotechnology companies that are developing and marketing innovative drugs. BB Biotech’s investment portfolio usually consists of 20 up to a maximum of 35 biotechnology companies. There are established, large-cap companies as well as small- and mid-cap companies in the portfolio. The asset classes available to BB Biotech are direct investments in the shares of listed companies, equity interests in unlisted companies, corporate bonds, and options on a range of underlying assets. Bellevue AM invests almost exclusively in stocks for liquidity and risk/return reasons. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. Corporate bonds are an alternative primarily when stock market trends are negative. Options on the stocks of portfolio companies will be bought and sold at opportune times and as a means of hedging currency exposure.

Investor at Alnylam Pharmaceuticals, Inc.

Cardinal Partners invests in life sciences, medical devices and healthcare information technology. The firm provides financing for early-stage companies with an investment size of $6 million to $12 million. It leads initial round of investment.

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.